Drug Trial Radar · NCT04619316
Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition
Last checked: Nov 19, 2026Latest source record: Jun 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
70
Planned (sponsor's estimate)
Start
Feb 5, 2018
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- University Hospital, EssenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective interventional trial that aims to restore iodine incorporation in tumoral lesions of patients with unresectable, radioiodine-refractory thyroid cancer.
Conditions
- Metastatic Thyroid Cancer
Interventions
Trametinib 2 MG [Mekinist]Drug
Monotherapy with Trametinib is given in patients with BRAF wildtype.
Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]Drug
Combination therapy is given in patients with BRAF V600E mutation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with sufficiently increased tumoral iodine incorporationTime frame: At the time point of 123I whole-body scintigraphy, 3 weeks after the start of redifferentiation therapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Manuel M. Weber
Essen, North Rhine-Westphalia, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.